These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2004-002799-41||Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders||2010-03-24||due-trials|
|Reported results||2005-003775-21||Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis||2008-11-24||due-trials|
|Reported results||2005-003871-19||A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease||2009-07-01||due-trials|
|Exempt, with results||2007-002337-36||An open-labelled study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® in patients with subarachnoid haemorrhage||2009-01-13||not-yet-due|
|Reported results||2007-002467-27||Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias||2011-05-31||due-trials|
|Exempt, with results||2007-005836-98||The effect of Kineret® on brain biomarkers in patients with subarachnoid haemorrhage||2010-07-01||not-yet-due|
|Reported results||2007-007482-21||Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE ...||2010-01-31||due-trials|
|Reported results||2009-015849-22||An open label study of intra-articular steroid injection in the management of symptomatic knee OA||2014-12-15||due-trials|
|Reported results||2011-001855-35||Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following subarachnoid haemorrhage?||2015-10-01||due-trials|
|Reported results||2013-001757-28||Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following ischaemic stroke compared to placebo?||2017-02-28||due-trials|